Synthetic Biology Market Trends and Overview

The size of the Synthetic Biology Market was estimated to be USD 13.1 billion in 2022, with a projected growth to reach USD 52.6 billion by 2030, reflecting a compound annual growth rate (CAGR) of 19.0% during the forecast period from 2023 to 2030.

Synthetic biology, a rapidly expanding field, is poised to revolutionize various industries through its innovative applications. With the market expected to experience significant growth over the next decade, it presents lucrative opportunities for investors and stakeholders.

The estimated market size of USD 13.1 billion in 2022 highlights the existing demand and adoption of synthetic biology solutions across diverse sectors. As the field continues to evolve and gain traction, the market is projected to witness substantial expansion, reaching a staggering USD 52.6 billion by 2030.

This impressive growth can be attributed to several factors. Firstly, the increasing need for sustainable and eco-friendly solutions in industries such as healthcare, agriculture, and energy has propelled the demand for synthetic biology. By harnessing the power of genetic engineering and biotechnology, synthetic biology offers innovative approaches to address complex challenges, ranging from developing novel therapeutics to enhancing crop yields and creating renewable energy sources.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3955

Furthermore, the rising investments in research and development activities, coupled with advancements in technology, are driving the growth of the synthetic biology market. Governments, private organizations, and academic institutions are actively investing in this field, recognizing its potential to revolutionize various sectors and contribute to economic growth.

The forecasted compound annual growth rate (CAGR) of 19.0% from 2023 to 2030 underscores the robust expansion expected in the synthetic biology market. This growth rate signifies the increasing adoption of synthetic biology solutions and the emergence of new applications and products in the coming years.

KEY MARKET SEGMENTATION:

By Technology

  • NGS Technology
  • PCR Technology
  • Genome Editing Technology
  • Bioprocessing Technology
  • Other Technologies

By Product

  • Oligonucleotide/Oligo Pools and Synthetic DNA
  • Enzymes
  • Cloning Technologies Kits
  • Xeno-Nucleic Acids
  • Chassis Organism

By Application

  • Healthcare
    • Clinical
    • Non-Clinical
  • Non-healthcare
    • Biotech Crops
    • Specialty Chemicals
    • Bio-fuels
    • Others

By End User

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Others

KEY PLAYERS:

The major key players are Bota Biosciences Inc., Codexis, Inc., Creative Biogene., Creative Enzymes., Enbiotix, Inc., Illumina, Inc., Merck Kgaa (Sigma-Aldrich Co. Llc), New England Biolabs, Euro fins Scientific, Novozymes, Pareto Bio, Inc., Synthetic Genomics Inc., Thermo Fisher Scientific, Inc., and Others.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com